Fig. 5
From: Tumor microenvironment-responsive BSA nanocarriers for combined chemo/chemodynamic cancer therapy
The blood circulation and biodistribution of GCBD NPs in mice. a The blood circulation of 125I@GCBD NPs in Balb-c mice after intravenous (i.v.) injection (20 µCi for 125I, 2.5 mg kg−1 of DOX). b The biodistribution of 125I-labeled GCBD NPs at 4 h (pink) and 24 h (gray) after i.v. injection (20  µCi for 125I, 2.5 mg kg−1 of DOX) as determined by measuring the radionuclide intensity in the major organs and tumors. c The fluorescence imaging of 4T1 tumor-bearing mice at different time points after i.v. administration of Cy5.5-labeled GCB NDs (10 mg kg−1) or GCBD NPs (2.5 mg kg−1 of DOX) (the tumor was highlighted by white dotted circle). The error bars were based on the standard deviation of tree mice in each group